Potassium Channel Blockers
"Potassium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS.
| Descriptor ID |
D026902
|
| MeSH Number(s) |
D27.505.519.562.500 D27.505.954.411.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Potassium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Potassium Channel Blockers".
This graph shows the total number of publications written about "Potassium Channel Blockers" by people in this website by year, and whether "Potassium Channel Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 3 | 3 |
| 2000 | 2 | 2 | 4 |
| 2001 | 1 | 0 | 1 |
| 2002 | 3 | 1 | 4 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 3 | 4 |
| 2012 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Potassium Channel Blockers" by people in Profiles.
-
Burashnikov A. Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020? J Cardiovasc Pharmacol. 2020 11; 76(5):492-505.
-
Burashnikov A, Barajas-Martinez H, Hu D, Robinson VM, Grunnet M, Antzelevitch C. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol. 2020 08; 76(2):164-172.
-
Stabenau HF, Shen C, Tereshchenko LG, Waks JW. Changes in global electrical heterogeneity associated with dofetilide, quinidine, ranolazine, and verapamil. Heart Rhythm. 2020 03; 17(3):460-467.
-
Camm AJ, Dorian P, Hohnloser SH, Kowey PR, Tyl B, Ni Y, Vandzhura V, Maison-Blanche P, de Melis M, Sanders P. A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation. Eur Heart J Cardiovasc Pharmacother. 2019 01 01; 5(1):21-28.
-
Chan KY, Chang RS, Lau VW, Chan ML, Lai T. Palliative care for a patient with Lambert-Eaton myasthenic syndrome: role of 3,4-diaminopyridine. Ann Palliat Med. 2016 Oct; 5(4):311-314.
-
Liu G, Liu T, Cohen D, Liu T, Yan GX. How to determine cardiac ion channels targeted by drugs using the isolated rabbit ventricular wedge model. J Pharmacol Toxicol Methods. 2016 Sep-Oct; 81:161-70.
-
Robinson VM, Kowey PR. Smoothing the Bumpy Road to Antiarrhythmic Drug Development. Circulation. 2015 Dec 08; 132(23):2195-7.
-
Doss MX, Di Diego JM, Goodrow RJ, Wu Y, Cordeiro JM, Nesterenko VV, Barajas-Mart?nez H, Hu D, Urrutia J, Desai M, Treat JA, Sachinidis A, Antzelevitch C. Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One. 2012; 7(7):e40288.
-
Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity. J Cardiovasc Pharmacol. 2012 Jun; 59(6):539-46.
-
Tabak J, Tomaiuolo M, Gonzalez-Iglesias AE, Milescu LS, Bertram R. Fast-activating voltage- and calcium-dependent potassium (BK) conductance promotes bursting in pituitary cells: a dynamic clamp study. J Neurosci. 2011 Nov 16; 31(46):16855-63.